Table II.
Phase II/III clinical trials of anti-angiogenic drugs for patients with metastatic colon cancers (modified from Nandikolla and Rajdev 2016) [35]
| Angiogenesis inhibitor |
Identification number |
Clinical trial | Primary Outcome | Phase |
|---|---|---|---|---|
| Afilbercept | NCT02331927 | PERMAD: Personalized Marker-driven Early Switch to Aflibercept in Patients With Metastatic Colorectal Cancer (PERMAD) | PFS | II |
| NCT02384759 | Aflibercept +/− LV5FU2 in First Line of Non-resectalbe Metastatic Colorectal Cancers (FOLFA) | Radiological PFS | II | |
|
| ||||
| Bevacizumab | NCT01640405 | Study of 5-Fluorouracil/Leucovorin/Oxaliplatin (FOLFOX) + Bevacizumab Versus 5-Fluorouracil/Leucovorin/Oxaliplatin/Irinotecan (FOLFOXIRI) + Bevacizumab as First Line Treatment of Patients With Metastatic Colorectal Cancer Not Previously Treated and With Three or More Circulating Tumoral Cells (VISNU-1) | PFS | III |
| NCT01718873 | Optimization of Bevacizumab Scheduling With Chemotherapy for Metastatic Colorectal Cancer (OBELICS) | No. of objective responses | III | |
| NCT01249638 | Combination of capecitabine and bevacizumab versus the combination of capecitabine, bevacizumab and irinotecan. | Time of failure strategy | III | |
| NCT02339116 | Folfoxiri Plus Bev Followed by Reintroduction of Folfoxiri Plus Bev at Progression Versus Folfox Plus Bev Followed by Folfiri Plus Bev in mCRC (TRIBE2) | PFS | III | |
| NCT02141295 | A Study Comparing the Efficacy and Safety of Vanucizumab and FOLFOX With Bevacizumab and FOLFOX in Participants With Untreated Metastatic Colorectal Cancer (McCAVE) | PFS | II | |
| NCT01206530 | FOLFOX/Bevacizumab/Hydroxychloroquine (HCQ) in Colorectal Cancer | Response rate | II | |
| NCT00200200 | Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combination With Chemotherapy With/Without Bevacizumab for Hepatic Metastases From Colorectal Cancer | TTP | II | |
| NCT00544700 | Bevacizumab in Treating Patients Who Have Undergone First-Line Therapy for Metastatic Colorectal Cancer | TTP | III | |
| NCT00217737 | Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer | Disease-free survival | III | |
| NCT00952029 | Combination Chemotherapy and Bevacizumab With or Without Bevacizumab Maintenance Therapy in Treating Patients With Metastatic Colorectal Cancer | Disease-control duration | III | |
| NCT00098787 | Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer | Objective response rate | II | |
| NCT01279681 | Combination Chemotherapy Plus Bevacizumab With or Without Oxaliplatin in Treating Older Patients With Metastatic Colorectal Cancer | PFS | III | |
|
| ||||
| Famitinib | NCT02390947 | Safety and Efficacy Study of Famitinib in Patients with Advanced Colorectal Adenocarcinoma (FACT) | OS | III |
|
| ||||
| Nintedanib | NCT02149108 | Nintedanib (BIBF 1120) vs Placebo in Refractory Metastatic Colorectal Cancer (LUME-Colon 1) | OS | III |
|
| ||||
| Panitumumab | NCT01814501 | Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab | PFS | II |
|
| ||||
| Ramucirumab | NCT01079780 | Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy | PFS | II |
|
| ||||
| Regorafenib | NCT02368886 | Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer | Proportion of patients in each arm who completed 2 courses of treatment | II |
|
| ||||
| Sorafenib | NCT00826540 | Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer | PFS | II |